Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Status:
Recruiting
Trial end date:
2023-09-02
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment
of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to
assess the efficacy of the drug combination via overall response rate and overall disease
control rate.
It is believed that giving olaparib and durvalumab together would be more useful when given
to patients with IDH-mutated solid tumors than giving each drug alone.